On May 17, 2016 NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, reported an update today on the company’s aNK, haNK and taNK clinical programs in a presentation at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada (Press release, NantKwest, MAY 17, 2016, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2168882 [SID:1234512456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of that presentation, additional details were shared on the following highlighted clinical studies all expected to be initiated in the second half of 2016:

The aNK Phase II clinical study in Merkel cell carcinoma is advancing as planned with an interim data analysis planned for the second half of 2016.
A HER2.taNK Phase I/II clinical study in glioblastoma and breast cancer
A haNK Phase I/II clinical study in breast cancer in combination with trastuzumab (Herceptin)
A haNK Phase I/II clinical study in breast cancer combination with trastuzumab and an adenovirus-based HER2 vaccine
A haNK Phase I/II clinical study in gastric cancer in combination trastuzumab and AMG337, an oral, small molecule MET inhibitor
A haNK Phase I/II clinical study in Ewing’s sarcoma in combination with ganitumab, a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R)
A haNK Phase I/II clinical study in rhabdomyosarcoma in combination with ganitumab and dasatinib
A haNK Phase I/II clinical study in bladder cancer in combination with ALT-803, a novel IL-15 based immune system stimulating agent
Commenting on NantKwest’s clinical progress, Patrick Soon-Shiong, MD, Chairman and CEO remarked, "The complex biology of cancer requires a similarly complex war against cancer that will require combination immunotherapy. We believe NantKwest’s novel, off-the-shelf natural killer cell therapy represents a critical backbone that enables the up regulation of both the innate immune system and the adaptive immune system to begin to successfully fight the war against cancer."

Dr. Soon-Shiong continued, "I am also pleased to announce that with the proceeds from our IPO, the company has rapidly expanded its manufacturing capabilities and with the infrastructure now in place, we are now ready to translate these programs into human clinical studies over the next 6-12 months and look forward to sharing more details on these individual clinical trials over the next few months."

To listen to the presentation in its entirety, the link to the presentation can be found on the NantKwest website at:

https://www.veracast.com/webcasts/baml/healthcare2016/id95107262726.cfm

in the investor relations section of the NantKwest website.